Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood

Cell-free DNA (cfDNA) analysis using peripheral blood represents an exciting, minimally invasive technology for cancer diagnosis and monitoring. The reliability of testing is dependent on the accuracy and sensitivity of specific molecular analyses to detect tumor-associated genomic variants and on t...

Full description

Saved in:
Bibliographic Details
Published in:The journal of applied laboratory medicine 2020-07, Vol.5 (4), p.788-797
Main Authors: Samoila, Aliaksandra, Sosa, Jose, Padilla, Jessica, Wutkowski, Michael, Vanness, Katelynd, Viale, Agnes, Berger, Michael, Houck-Loomis, Brian, Pessin, Melissa, Peerschke, Ellinor I
Format: Article
Language:English
Subjects:
Blood Specimen Collection - standards
Circulating Tumor DNA - genetics
Circulating Tumor DNA - isolation & purification
Clinical Laboratory Services - organization & administration
Clinical Laboratory Services - standards
DNA Mutational Analysis
Guidelines as Topic
Humans
Mutation
Neoplasms - blood
Neoplasms - diagnosis
Neoplasms - genetics
Quality Control
Quality Improvement
Reproducibility of Results
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell-free DNA (cfDNA) analysis using peripheral blood represents an exciting, minimally invasive technology for cancer diagnosis and monitoring. The reliability of testing is dependent on the accuracy and sensitivity of specific molecular analyses to detect tumor-associated genomic variants and on the quantity and quality of cfDNA available for testing. Specific guidelines for standardization and design of appropriate quality programs focused specifically on cfDNA isolation are lacking, as are standardized quality control reagents. This report describes and illustrates quality control and quality assurance processes, supported by generation of in-house quality control material, to ensure the reliability of the preanalytical phase of cfDNA analysis. We have developed a robust quality program to support high-volume automated cfDNA extraction from peripheral blood by implementing processes and procedures designed to monitor the adequacy of specimen collection, specimen stability, efficiency of cfDNA extraction, and cfDNA quality.
ISSN:2576-9456
2475-7241
DOI:10.1093/jalm/jfaa050